• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by AtriCure Inc.

    8/12/25 10:34:24 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care
    Get the next $ATRC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    AtriCure, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    04963C209

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    04963C209


    1Names of Reporting Persons

    Wellington Management Group LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,342,505.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,969,269.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,969,269.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    04963C209


    1Names of Reporting Persons

    Wellington Group Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,342,505.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,969,269.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,969,269.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    04963C209


    1Names of Reporting Persons

    Wellington Investment Advisors Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,342,505.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,969,269.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,969,269.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    04963C209


    1Names of Reporting Persons

    Wellington Management Company LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,342,505.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,377,947.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,969,269.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.8 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    AtriCure, Inc.
    (b)Address of issuer's principal executive offices:

    7555 Innovation Way, Mason OH 45040
    Item 2. 
    (a)Name of person filing:

    Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP
    (b)Address or principal business office or, if none, residence:

    c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
    (c)Citizenship:

    Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    04963C209
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the responses to Item 9 on the attached cover pages.
    (b)Percent of class:

    8.02  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    See the responses to Item 8 on the attached cover pages.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Wellington Management Group LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:08/12/2025
     
    Wellington Group Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:08/12/2025
     
    Wellington Investment Advisors Holdings LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:08/12/2025
     
    Wellington Management Company LLP
     
    Signature:Taisia Lowe
    Name/Title:Regulatory Analyst
    Date:08/12/2025
    Get the next $ATRC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATRC

    DatePrice TargetRatingAnalyst
    12/17/2024$40.00Overweight
    Analyst
    4/23/2024$32.00Perform → Outperform
    Oppenheimer
    10/23/2023$60.00Mkt Outperform
    JMP Securities
    9/29/2023$56.00Buy
    UBS
    2/16/2022$120.00 → $88.00Buy
    Canaccord Genuity
    2/16/2022$92.00 → $79.00Buy
    Needham
    11/4/2021$90.00 → $92.00Buy
    Needham
    11/4/2021$100.00 → $110.00Outperform
    SVB Leerink
    More analyst ratings

    $ATRC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AtriCure Announces the First Patients Treated with Novel Dual Energy Platform

    New technology combines Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation with AtriCure's EnCompass® clamp to reduce treatment time for surgical ablation patients AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced successful first-in-human treatments using its novel dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA). The procedures were performed by Dr. Adrian Pick in collaboration with the site Principal Investigator Professor Jayme Bennetts, at Victorian He

    12/11/25 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference

    AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference. AtriCure's management is scheduled to participate in a fireside discussion on Tuesday, December 2, 2025, at 10:00 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related c

    11/18/25 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025

    Worldwide revenue of $134.3 million – an increase of 15.8% year over year (15.1% constant currency) Net loss of $0.3 million – an improvement of $7.6 million year over year Adjusted EBITDA of $17.8 million – an increase of $9.9 million year over year Generated $30.1 million of cash in the third quarter and $25.1 million year to date AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2025 financial results. "Our third quarter results demonstrate strong execution and patient focus across the business. We are

    10/29/25 4:01:00 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Privitera Salvatore bought $111,250 worth of shares (5,000 units at $22.25), increasing direct ownership by 5% to 103,290 units (SEC Form 4)

    4 - AtriCure, Inc. (0001323885) (Issuer)

    5/31/24 4:12:34 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    SEC Filings

    View All

    SEC Form 144 filed by AtriCure Inc.

    144 - AtriCure, Inc. (0001323885) (Subject)

    11/25/25 4:06:42 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by AtriCure Inc.

    144 - AtriCure, Inc. (0001323885) (Subject)

    11/24/25 5:41:59 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by AtriCure Inc.

    10-Q - AtriCure, Inc. (0001323885) (Filer)

    10/30/25 12:21:59 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CEO, & Director Carrel Michael H gifted 4,000 shares, decreasing direct ownership by 0.58% to 687,377 units (SEC Form 4)

    4 - AtriCure, Inc. (0001323885) (Issuer)

    12/12/25 8:26:40 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    Director Wehrwein Sven exercised 10,000 shares at a strike of $19.95 and sold $376,578 worth of shares (10,000 units at $37.66) (SEC Form 4)

    4 - AtriCure, Inc. (0001323885) (Issuer)

    11/26/25 4:43:11 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    Chief Mktg & Strategy Officer Noznesky Justin J sold $192,640 worth of shares (5,166 units at $37.29), decreasing direct ownership by 6% to 78,798 units (SEC Form 4)

    4 - AtriCure, Inc. (0001323885) (Issuer)

    11/26/25 4:41:44 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst resumed coverage on AtriCure with a new price target

    Analyst resumed coverage of AtriCure with a rating of Overweight and set a new price target of $40.00

    12/17/24 7:29:01 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded AtriCure from Perform to Outperform and set a new price target of $32.00

    4/23/24 6:23:54 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    JMP Securities initiated coverage on AtriCure with a new price target

    JMP Securities initiated coverage of AtriCure with a rating of Mkt Outperform and set a new price target of $60.00

    10/23/23 7:18:47 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Leadership Updates

    Live Leadership Updates

    View All

    AtriCure Appoints Shlomi Nachman to the Board of Directors

    AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors. Mr. Nachman's long and distinguished career in the medical device industry has placed him at the forefront of new market development and growth, serving most recently as Company Group Chairman within Johnson & Johnson's Medical Devices business. Mr. Nachman has over 25 years of experience in the medical device industry and is currently on the board of several private medical device companies, as well as the Arnold and Mable Beck

    1/4/24 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer

    AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effective today. Ms. Yount will have responsibility for global Human Resources activities. "We are excited to have Deborah joining us at AtriCure," said Michael Carrel, President and Chief Executive Officer. "She brings an incredible amount of industry and human capital expertise as we enter a period of accelerated growth. Our opportunities to address the global Afib epidemic and help patients manage post-operative pain are profo

    6/1/22 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Financials

    Live finance-specific insights

    View All

    AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025

    Worldwide revenue of $134.3 million – an increase of 15.8% year over year (15.1% constant currency) Net loss of $0.3 million – an improvement of $7.6 million year over year Adjusted EBITDA of $17.8 million – an increase of $9.9 million year over year Generated $30.1 million of cash in the third quarter and $25.1 million year to date AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2025 financial results. "Our third quarter results demonstrate strong execution and patient focus across the business. We are

    10/29/25 4:01:00 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure to Announce Third Quarter 2025 Financial Results

    AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2025 financial results on Wednesday, October 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, October 29, 2025, to discuss its third quarter 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at

    10/8/25 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025

    Worldwide revenue of $136.1 million – an increase of 17.1% year over year (16.5% constant currency) Net loss of $6.2 million – an improvement of $1.8 million year over year Adjusted EBITDA of $15.4 million – an increase of $7.6 million year over year Generated $17.9 million of cash in the quarter Completed enrollment of all 6,500 patients in the ground-breaking LeAAPS trial AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2025 financial results. "Our stellar results reflect the power of innovation and the

    7/29/25 4:01:00 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by AtriCure Inc.

    SC 13G - AtriCure, Inc. (0001323885) (Subject)

    11/14/24 8:00:04 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

    SC 13G/A - AtriCure, Inc. (0001323885) (Subject)

    2/14/24 2:56:38 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

    SC 13G/A - AtriCure, Inc. (0001323885) (Subject)

    2/13/24 4:58:56 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care